Supporting Healthcare, Managing COVID-19
503B outsourcing facilities are a ‘must-have’ resource in the midst of America’s current healthcare pandemic. As hospitals and front-line workers continue to navigate influx along with a new socially distanced and mask wearing normal, patient experience continues to evolve. Ambulatory surgery centers are wading through state go no-go restrictions on elective surgeries, new regulations, and potential testing bottlenecks, all while balancing continued need for their services.
Labor shortages and increased demand on medications to fight COVID-19 have necessitated hospital pharmacies and surgery centers to seek outside assistance for drugs necessary to support viable patient treatment options for the critically ill.
According to The Bureau of Investigative Journalism, when drugs are in short supply, doctors must rely on alternatives that may be unfamiliar or have greater side-effects. They may also be forced to adopt measures that potentially increase the risk to certain patients in order to conserve medication for others . Instead of relying on internal pharmacy compounding, 503B outsourcing may be a more efficient and safer alternative.
Supply Chain Strain
As the corona virus has permeated, the FDA diligently monitors the medical supply chain for disruptions and shortages that would have a catastrophic effect on patient care. However, major distributors of active ingredients in medications such as China and India, have experienced slowdowns in manufacturing because of a reduced workforce.
Even as current restrictions are lifted and more elective-surgeries are scheduled, ambulatory surgery centers and physician offices continue to increase the demand for these medications. A 503B outsourcing facility is a practical means to supply critical medications when a hospital is unable to do so and may have other benefits.
503B Outsourcing You Can Rely On
Fagron Sterile Services US (FSS), an FDA and DEA registered 503B, continues to expand their Operating Room (O.R.) Anesthesia portfolio to support healthcare customers across the country. This includes the addition of a new IV Bag platform.
FSS was able to move quickly and respond at the onset of COVID-19 with multiple medications used in the battle against this highly contagious virus. Many of these products have since been listed on drug shortage lists by the American Society of Health-System Pharmacists (ASHP) and the Food and Drug Administration.
FSS continues to deliver industry leading turnaround times of high-quality sterile medications to hospitals, ambulatory surgery centers, clinics, and physician offices. To ensure top-tier service, FSS took supply chain precautions regarding COVID-19 and performed risk assessments of its products and the raw materials (read more).
To date, there have not been any significant disruptions to the availability of FSS products and services. View a full product catalog and learn more about FSS independent aseptic processing environments, industry leading automation, advanced environmental monitoring and in-house laboratory testing.
FSS integrates state-of-the-art quality to provide a reliable supply of 503B outsourcing to clinicians and the patients they serve across the United States. All FSS manufacturing facilities are registered and inspected by the FDA and DEA.
 Davies, Madlen, et al. “Drug Shortages Put Worst-Hit Covid-19 Patients at Risk.” The Bureau of Investigative Journalism, The Bureau of Investigative Journalism, 17 Apr. 2020, Source Link.